AeRang Kim
Professor of Pediatrics
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Purpose: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of neurofibromatosis type 1 (NF1)–related tumors, caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical benefit rate in patients with unresectable/metastatic MPNST. Patients and Methods: The study design was a multi-institutional, open-label, Simon two-stage, phase II study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50 mg twice daily and sirolimus 4 mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA). Results: A total of 21 heavily pretreated patients [seven females; median age, 41 years (range, 16–72); and 14 with NF1] with advanced disease enrolled at five participating sites. Clinical benefit was observed in only one of seven in stage 1 and one of 14 patients in stage 2. The median number of cycles was two (range, 1–6). Most common adverse events (AE) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18F-fluorodeoxyglucose PET scan performed during cycle 1 demonstrated partial metabolic responses in five patients (24%), but these did not correlate with objective responses after cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response. Conclusions: The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.
Year:
2026
Year:
2025
Background This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRAF V600 mutated kinase, in patients with relapsed or refractory solid tumors harboring BRAF V600 mutations. Methods Patients received vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles until progression or intolerable toxicity. The primary aim was to determine the objective response rate and secondary objectives included estimating progression-free survival and assessing the tolerability of vemurafenib. Results Twenty-two patients matched to the subprotocol and 4 patients (18%) enrolled. Primary reasons for non-enrollment were ineligibility due to exclusions of low-grade glioma (n = 7) and prior BRAF inhibitor therapy (n = 7). Enrolled diagnoses were one each of histiocytosis, ameloblastoma, Ewing sarcoma, and high-grade glioma, all with BRAF V600E mutations. Treatment was overall tolerable with mostly expected grade 1/2 adverse events (AE). Grade 3 or 4 AE on treatment were acute kidney injury, hyperglycemia, and maculopapular rash. One patient came off therapy due to AE. One patient (glioma) had an objective partial response and remained on protocol therapy for 15 cycles. Conclusion There was a low accrual rate on this MATCH subprotocol, with only 18% of those who matched with BRAFV600 mutations enrolling, resulting in early termination, and limiting study results (ClinicalTrials.gov Identifier: NCT03220035).
Year:
2024
Supplemental Figure 1. Attributes of atypical neurofibroma samples. Histologic characteristics and, when available, TSO500 clinical sequencing results for paired tissue corresponding with AN cell-free DNA.
Year:
2024
Purpose: Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe a cell-free DNA (cfDNA) fragmentomic approach that distinguishes nonmalignant, premalignant, and malignant forms of PNST in the cancer predisposition syndrome, NF1. Experimental Design: cfDNA was isolated from plasma samples of a novel cohort of 101 patients with NF1 and 21 healthy controls and underwent whole-genome sequencing. We investigated diagnosis-specific signatures of copy-number alterations with in silico size selection as well as fragment profiles. Fragmentomics were analyzed using complementary feature types: bin-wise fragment size ratios, end motifs, and fragment non-negative matrix factorization signatures. Results: The novel cohort of patients with NF1 validated that our previous cfDNA copy-number alteration–based approach identifies malignant PNST (MPNST) but cannot distinguish between benign and premalignant states. Fragmentomic methods were able to differentiate premalignant states including atypical neurofibromas (AN). Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management. Conclusions: Novel cfDNA fragmentomic signatures distinguish AN from benign plexiform neurofibromas and MPNST, enabling more precise clinical diagnosis and management. This study pioneers the early detection of malignant and premalignant PNST in NF1 and provides a blueprint for decentralizing noninvasive cancer surveillance in hereditary cancer predisposition syndromes.
Year:
2024
Supplemental Figure 2. Diminishing improvements in accuracy with deeper sequencing. MPNST samples sequenced to ∼25x were downsampled in five iterations per goal coverage (Methods). Size selected, copy number derived tumor fraction variability was noted between iterations less than or equal to 3x with statistically significant differences in tumor fraction (*, Welch’s T-test) between 25x coverage and 3x or below sequencing depths. No statistical difference (ns) was noted in tumor fraction between 25x coverage and sequencing depths greater than or equal to 6x.
Year:
2024
Supplemental Figure 4. 4-mer end motifs across F-profiles. Comprehensive view of the distribution and prevalence of each possible 4-mer end motif within each of the six distinct F-profiles derived from non-negative matrix factorization (NMF) (Methods). The analysis highlights distinct end motif compositions and non-random distribution of end nucleotides across the F-profiles.
Year:
2024
Supplemental Figure 3. Number of NMF components versus AUC. Performance (AUC) of NMF models in OVO comparisons is plotted against the number n components (Methods) used. The number of components approaches the AUC’s asymptote in each OVO at or before 20 components. Optimal number of components for each OVO was defined as the number of components yielding the highest AUC. AUC, area under the curve; OVO, one-versus-one comparison; NMF, non-negative matrix factorization.
Year:
2024
Early detection of neurofibromatosis type 1 (NF1) associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, potentially averting deadly outcomes. Here, we describe a cell-free DNA (cfDNA) fragmentomic approach which distinguishes non-malignant, pre-malignant and malignant forms of NF1 PNST. Using plasma samples from a novel cohort of 101 NF1 patients and 21 healthy controls, we validated that our previous cfDNA copy number alteration (CNA)-based approach identifies malignant peripheral nerve sheath tumor (MPNST) but cannot distinguish among benign and premalignant states. We therefore investigated the ability of fragment-based cfDNA features to differentiate NF1-associated tumors including binned genome-wide fragment length ratios, end motif analysis, and non-negative matrix factorization deconvolution of fragment lengths. Fragmentomic methods were able to differentiate pre-malignant states including atypical neurofibromas (AN). Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management. Overall, this study pioneers the early detection of malignant and premalignant peripheral nerve sheath tumors in NF1 patients using plasma cfDNA fragmentomics. In addition to screening applications, this novel approach distinguishes atypical neurofibromas from benign plexiform neurofibromas and malignant peripheral nerve sheath tumors, enabling more precise clinical diagnosis and management.
Year:
2024
Year:
2023
Collaborators (18)
Karla Ballman
Chair / Consultant / Professor of Biostatistics
Mayo Clinic College of Medicine and Science
Christine A Pratilas
Vice Chair for Pediatric Oncology
Johns Hopkins University School of Medicine
Russell Taylor Sundby
Assistant Professor
Thomas Jefferson University
Paul Jones
Washington University in St. Louis
Jeffrey Szymanski
Assistant Professor
Mayo Clinic Minnesota
Rashmi Chugh
-
Karen Cichowski
Professor
Brigham and Women's Hospital
Aadel A. Chaudhuri
Washington University School of Medicine
Angela C. Hirbe
Washington University School of Medicine
Andrea Gross
Associate Professor
Cincinnati Children's Hospital Medical Center
Robert G. Maki
Professor, Member
-
Jack Shern
Head, Tumor Evolution and Genomics Section
National Institutes of Health
Scott Bradfield
Interim Division Chief
Nemours Children's Health System
Donald Parsons
Professor
Baylor College of Medicine
Scott Borinstein
Professor
Vanderbilt University Medical Center
John S A Chrisinger
Washington University in St. Louis
Carina A Dehner
Assistant Professor
University of Pennsylvania
Amy Armstrong
Associate Professor in Pediatrics
Washington University Physicians
Make your next move.
Prepare your application
Review drafts before you send them.